Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial

The Lancet. Haematology
Eytan M SteinHagop M Kantarjian

Abstract

Mutations in isocitrate dehydrogenase-2 (IDH2) occur in around 5% of patients with myelodysplastic syndromes. Neomorphic activity of mutant IDH2 proteins results in hypermethylation of DNA and histones, leading to blocked haemopoietic differentiation. Enasidenib, an inhibitor of mutated IDH2 proteins, induces responses in patients with IDH2-mutated, relapsed or refractory acute myeloid leukaemia. We aimed to establish the clinical outcomes of enasidenib monotherapy in a subgroup of patients with myelodysplastic syndromes harbouring mutations in IDH2 from the AG221-C-001 trial. The multicentre, open-label, phase 1-2 AG221-C-001 trial enrolled patients with advanced haematological malignancies (2008 WHO criteria) harbouring an IDH2 mutation. The present study is a subgroup analysis of patients with IDH2-mutated myelodysplastic syndromes in the phase 1 dose-escalation and expansion portions of the trial. Patients with myelodysplastic syndromes were aged 18 years or older with an ECOG performance status score of 2 or lower, and were relapsed or refractory to, or ineligible for, standard treatments. Patients received oral doses of enasidenib at 60-300 mg per day in repeated 28-day treatment cycles. In this subgroup analysis, we focu...Continue Reading

Citations

Jun 2, 2020·Expert Review of Anticancer Therapy·Jonathan FeldShyamala C Navada
May 23, 2020·Haematologica·Eva Hellström-LindbergPeter Greenberg
Oct 1, 2020·The New England Journal of Medicine·Mario Cazzola
Feb 6, 2021·Experimental Biology and Medicine·Zhimei CaiHaiqing Wang
Jan 13, 2021·Cells·Haemin KimKyung-Hyun Park-Min
Jan 30, 2021·Seminars in Hematology·Jesus D Gonzalez-LugoAditi Shastri
Jan 30, 2021·Frontiers in Cell and Developmental Biology·Zhen WeiPing Yi
Mar 26, 2021·Best Practice & Research. Clinical Haematology·Terra Lasho, Mrinal M Patnaik
Nov 28, 2020·Biochimica Et Biophysica Acta. Molecular Basis of Disease·Gabriela L OliveiraPaulo J Oliveira
Aug 31, 2020·Clinical Lymphoma, Myeloma & Leukemia·Stéphane de Botton
May 20, 2021·American Society of Clinical Oncology Educational Book·Robert P HasserjianMrinal M Patnaik
May 29, 2021·Leukemia·Uwe PlatzbeckerThomas Prebet
Jun 17, 2021·Nature Reviews. Clinical Oncology·Christopher J Pirozzi, Hai Yan
Jun 22, 2021·Leukemia & Lymphoma·Lori A RamkissoonJoshua F Zeidner
Jul 2, 2021·Clinical Lymphoma, Myeloma & Leukemia·Matteo Dragani, Stéphane de Botton
Aug 4, 2021·Drugs & Aging·Rory M Shallis, Amer M Zeidan
Jun 12, 2021·Blood·Jeffrey E Rubnitz, Gertjan J L Kaspers
Oct 11, 2021·British Journal of Haematology·Nina KimKelly J Norsworthy
Sep 3, 2021·Current Opinion in Oncology·Valeria Santini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.